SlideShare uma empresa Scribd logo
1 de 19
CASE PRESENTATION
ON
RHEUMATOID ARTHRITIS,
POLYARTHRITIS
My patient was a 35 year old female from
female ward of general medicine department.
I.P NO. : 51979
D.O.A : 26.11.15
SUBJECTIVE
REASON FOR ADMISSION : c/o abdominal discomfort,
joint pains. Vomiting past one month.
PAST MEDICAL HISTORY : Patient is steroid
dependent(can’t survive without these tablets)
not k/c/o DM,HTN
PAST MEDICATION HISTORY : on regular medication
past 10 years. T. Dexamethasone 0.5mg
T.Phenyl butazone
KNOWN ALLERGIES : Nil
SMOKER : No
ALCOHOLIC : No
TOBACCO IN ANY FORM : No
MARITAL STATUS : Married
OBJECTIVE
LABORATORY INVESTIGATIONS:
Blood Pressure, Cell Blood Count, Renal Function Test.
GENERAL INVESTIGATION :
Patient is conscious, weak, afebrile, poorly built. She is
steroid dependent from past 10 years.
LABORATORY REPORTS
ELECTROLYTES
Date 26-11-15 27-11-15
Blood Pressure 110/70 110/70
Electrolytes Normal value(mEq/L) Patient’s value(mEq/L)
Sodium 130-150 134
Potassium 3.5-5.8 4.42
Chloride 98-100 106
BLOOD COUNTS
CELLS NORMAL VALUE PATIENT VALUE
HEAMOGLOBIN
(g/dl)
M 12-16
F 11-14
10
TLC(cells/cumm) 5000-10000 9500
PLATELETS 1-3 lakh
POLYMORPHS 40-60 65
LYMPHOCYTES 20-30 27
BASOPHILS 0-1 00
EOSINOPHILS 1-4 04
MONOCYTES 1-2 04
RENAL FUNCTION TEST
Normal Value Patient Value
UREA(mg%) 15-45 61
URIC ACID(mg%) F 2-5
M 2-7
CREATININE(mg%) 0.6-1.4 2.6
ASSESSMENT
 Patient was diagnosed with Arthritis, Polyarthritis.
 Patient was steroid dependent from past 10 years.
 Patient had vomiting since one month.
 Patient has abnormal urea and creatinine value.
Urea - 61 mg%
Creatinine - 2.6 mg%
S.No TRADE NAME GENERIC
NAME
FREQU
ENCY
DAYS
01 Inj.Pantop IV
(40mg)
Pantoprazole
sodium
1-0-1 26/11/15 to 29/11/15
02 Inj.Emest (4mg) Ondansetron 1-1-1 26/11/15 to 29/11/15
03 T.Dolo(650mg) Paracetamol 1-1-1 26/11/15 to 27/11/15
04 T.Dexamethasone
(0.5mg)
Dexamethasone 1-0-1/2 26/11/15 to 29/11/15
05 T.TRP Tremadol +
Paracetamol
1-0-1 27/11/15 to 29/11/15
06 T.HCQ(200mg) Hydroxychloroqui
ne sulphate
1-0-0 27/11/15 to 29/11/15
TREATMENT PLAN
S.No. TRADE NAME GENERIC
NAME
FREQUE
NCY
DAYS
07 Pirox(40mg) Piroxicam 1-0-1 26/11/15
08 IVF 10NS Normal
saline
50ml/hr 26/11/15 to 29/11/15
DAY 1
• Patient had vomiting hence was very weak.
• Normal saline IVF was given to compensate
electrolyte loss.
• Renal function test report showed some
abnormalities in urea and serum creatinine
level.
• Inj.Pantop, Inj.Emeset, T. Dolo and
Dexamethasone, Normal saline, Piroxicam was
started.
• Blood pressure was normal.
DAY 2
• Patient now had less episodes of vomiting.
• Piroxicam was stopped.
• T.TRP, T.HCQ was started as she still had
complance of sever joint pain.
• All other medications were continued as per the
treatment chart.
• Blood pressure was recorded as normal.
DAY 3
• No episodes of vomiting was noticed.
• Emeset was continued to prevent vomiting due
to side effects of other drugs(dexamethasone,
tramadol, piroxicam)
• Patient started showing positive signs to the
treatment given.
• Medications continued as per the treatment
chart.
DAY 4
• Patient feels better.
• Medications continued as per the treatment
chart.
DRUG INTERRACTION
• HCQ-ONDANSETRON : MAJOR
Concurrent use of HCQ and QT prolonging
agents may result in increased risk of QT
prolongation.
• ONDANSETRON-TRP : MODERATE
Concurrent use of ondansetron and tramadol
may result in reduced efficacy of tramadol.
• Piroxicam, dexamethasone, tramadol, pantop,
hydroxychloroquine sulfate are contraindicative
in pregnant and lactating mothers.
PHARMACIST INTERVENSION
SUGGESSIONS TO PHYSICIAN:
• Emeset should not be given with HCQ and Tramadol.
• Drug duplication to be checked.
• Phenylbutazone has to be discontinued as it has major side
effect i.e kidney damage.(refer renal function test report)
SUGGESSIONS TO PATIENT:
• Inform physician in case of any side effects.
• Donot discontinue Dexamethasone until directed by a
physician as it has unpleasant withdrawal symptoms.
• Increase intake of calcium rich food.
• Take the medication properly as it will improve the quality
of life.
DISCHARGE CHART
 No discharge medication is available
rheumatoud arthritis and polyarthritis  ppt

Mais conteúdo relacionado

Semelhante a rheumatoud arthritis and polyarthritis ppt

Empty sella presentation oncall duty .pptx
Empty sella presentation oncall duty .pptxEmpty sella presentation oncall duty .pptx
Empty sella presentation oncall duty .pptx
HamadAlablani2
 
Case Presentation on Diabetes Mellitus complications
Case Presentation on Diabetes Mellitus complicationsCase Presentation on Diabetes Mellitus complications
Case Presentation on Diabetes Mellitus complications
ShivankAgrawal5
 
Choriocarcinoma management in a patient with superimposed malaria and typhoid
Choriocarcinoma management in a patient with superimposed malaria and typhoidChoriocarcinoma management in a patient with superimposed malaria and typhoid
Choriocarcinoma management in a patient with superimposed malaria and typhoid
pharmben
 
Anti tuberculosis drug - induced hepatitis – A Case Study
Anti tuberculosis drug - induced hepatitis – A Case StudyAnti tuberculosis drug - induced hepatitis – A Case Study
Anti tuberculosis drug - induced hepatitis – A Case Study
velspharmd
 

Semelhante a rheumatoud arthritis and polyarthritis ppt (20)

Soap format on dvt
Soap format on dvtSoap format on dvt
Soap format on dvt
 
Gastrocon 2016 - Drug Induced Liver Disease
Gastrocon 2016 - Drug Induced Liver DiseaseGastrocon 2016 - Drug Induced Liver Disease
Gastrocon 2016 - Drug Induced Liver Disease
 
Empty sella presentation oncall duty .pptx
Empty sella presentation oncall duty .pptxEmpty sella presentation oncall duty .pptx
Empty sella presentation oncall duty .pptx
 
Hepatoma.pptx
Hepatoma.pptxHepatoma.pptx
Hepatoma.pptx
 
Seizure
Seizure Seizure
Seizure
 
Saf presentation
Saf presentationSaf presentation
Saf presentation
 
SOAPping MI
SOAPping MISOAPping MI
SOAPping MI
 
Case Presentation on Diabetes Mellitus complications
Case Presentation on Diabetes Mellitus complicationsCase Presentation on Diabetes Mellitus complications
Case Presentation on Diabetes Mellitus complications
 
Endocrine causes of hypertension
Endocrine causes of hypertension Endocrine causes of hypertension
Endocrine causes of hypertension
 
Mi
MiMi
Mi
 
199563394 case-study-dengue
199563394 case-study-dengue199563394 case-study-dengue
199563394 case-study-dengue
 
A case study on Pangastritis with pancreatitis
A case study on Pangastritis with pancreatitis A case study on Pangastritis with pancreatitis
A case study on Pangastritis with pancreatitis
 
Choriocarcinoma management in a patient with superimposed malaria and typhoid
Choriocarcinoma management in a patient with superimposed malaria and typhoidChoriocarcinoma management in a patient with superimposed malaria and typhoid
Choriocarcinoma management in a patient with superimposed malaria and typhoid
 
Anti tuberculosis drug - induced hepatitis – A Case Study
Anti tuberculosis drug - induced hepatitis – A Case StudyAnti tuberculosis drug - induced hepatitis – A Case Study
Anti tuberculosis drug - induced hepatitis – A Case Study
 
CKD MBD - Drug Related Issues - Dr. Gawad
CKD MBD - Drug Related Issues - Dr. GawadCKD MBD - Drug Related Issues - Dr. Gawad
CKD MBD - Drug Related Issues - Dr. Gawad
 
D.G.F. CME CASE STUDY DISCUSSION Abnormal Uterine Bleeding
D.G.F. CME CASE STUDY DISCUSSIONAbnormal Uterine BleedingD.G.F. CME CASE STUDY DISCUSSIONAbnormal Uterine Bleeding
D.G.F. CME CASE STUDY DISCUSSION Abnormal Uterine Bleeding
 
D.G.F. CME CASE STUDY DISCUSSION Abnormal Uterine Bleeding
D.G.F. CME CASE STUDY DISCUSSIONAbnormal Uterine BleedingD.G.F. CME CASE STUDY DISCUSSIONAbnormal Uterine Bleeding
D.G.F. CME CASE STUDY DISCUSSION Abnormal Uterine Bleeding
 
Undifferentiated schizophrenia
Undifferentiated schizophreniaUndifferentiated schizophrenia
Undifferentiated schizophrenia
 
E053026029
E053026029E053026029
E053026029
 
Thrombus everywhere
Thrombus everywhereThrombus everywhere
Thrombus everywhere
 

Último

ppt your views.ppt your views of your college in your eyes
ppt your views.ppt your views of your college in your eyesppt your views.ppt your views of your college in your eyes
ppt your views.ppt your views of your college in your eyes
ashishpaul799
 
The basics of sentences session 4pptx.pptx
The basics of sentences session 4pptx.pptxThe basics of sentences session 4pptx.pptx
The basics of sentences session 4pptx.pptx
heathfieldcps1
 
IATP How-to Foreign Travel May 2024.pdff
IATP How-to Foreign Travel May 2024.pdffIATP How-to Foreign Travel May 2024.pdff
IATP How-to Foreign Travel May 2024.pdff
17thcssbs2
 

Último (20)

Matatag-Curriculum and the 21st Century Skills Presentation.pptx
Matatag-Curriculum and the 21st Century Skills Presentation.pptxMatatag-Curriculum and the 21st Century Skills Presentation.pptx
Matatag-Curriculum and the 21st Century Skills Presentation.pptx
 
Post Exam Fun(da) Intra UEM General Quiz - Finals.pdf
Post Exam Fun(da) Intra UEM General Quiz - Finals.pdfPost Exam Fun(da) Intra UEM General Quiz - Finals.pdf
Post Exam Fun(da) Intra UEM General Quiz - Finals.pdf
 
factors influencing drug absorption-final-2.pptx
factors influencing drug absorption-final-2.pptxfactors influencing drug absorption-final-2.pptx
factors influencing drug absorption-final-2.pptx
 
[GDSC YCCE] Build with AI Online Presentation
[GDSC YCCE] Build with AI Online Presentation[GDSC YCCE] Build with AI Online Presentation
[GDSC YCCE] Build with AI Online Presentation
 
MichaelStarkes_UncutGemsProjectSummary.pdf
MichaelStarkes_UncutGemsProjectSummary.pdfMichaelStarkes_UncutGemsProjectSummary.pdf
MichaelStarkes_UncutGemsProjectSummary.pdf
 
INU_CAPSTONEDESIGN_비밀번호486_업로드용 발표자료.pdf
INU_CAPSTONEDESIGN_비밀번호486_업로드용 발표자료.pdfINU_CAPSTONEDESIGN_비밀번호486_업로드용 발표자료.pdf
INU_CAPSTONEDESIGN_비밀번호486_업로드용 발표자료.pdf
 
The Benefits and Challenges of Open Educational Resources
The Benefits and Challenges of Open Educational ResourcesThe Benefits and Challenges of Open Educational Resources
The Benefits and Challenges of Open Educational Resources
 
How to Manage Notification Preferences in the Odoo 17
How to Manage Notification Preferences in the Odoo 17How to Manage Notification Preferences in the Odoo 17
How to Manage Notification Preferences in the Odoo 17
 
REPRODUCTIVE TOXICITY STUDIE OF MALE AND FEMALEpptx
REPRODUCTIVE TOXICITY  STUDIE OF MALE AND FEMALEpptxREPRODUCTIVE TOXICITY  STUDIE OF MALE AND FEMALEpptx
REPRODUCTIVE TOXICITY STUDIE OF MALE AND FEMALEpptx
 
Capitol Tech Univ Doctoral Presentation -May 2024
Capitol Tech Univ Doctoral Presentation -May 2024Capitol Tech Univ Doctoral Presentation -May 2024
Capitol Tech Univ Doctoral Presentation -May 2024
 
BỘ LUYỆN NGHE TIẾNG ANH 8 GLOBAL SUCCESS CẢ NĂM (GỒM 12 UNITS, MỖI UNIT GỒM 3...
BỘ LUYỆN NGHE TIẾNG ANH 8 GLOBAL SUCCESS CẢ NĂM (GỒM 12 UNITS, MỖI UNIT GỒM 3...BỘ LUYỆN NGHE TIẾNG ANH 8 GLOBAL SUCCESS CẢ NĂM (GỒM 12 UNITS, MỖI UNIT GỒM 3...
BỘ LUYỆN NGHE TIẾNG ANH 8 GLOBAL SUCCESS CẢ NĂM (GỒM 12 UNITS, MỖI UNIT GỒM 3...
 
“O BEIJO” EM ARTE .
“O BEIJO” EM ARTE                       .“O BEIJO” EM ARTE                       .
“O BEIJO” EM ARTE .
 
ppt your views.ppt your views of your college in your eyes
ppt your views.ppt your views of your college in your eyesppt your views.ppt your views of your college in your eyes
ppt your views.ppt your views of your college in your eyes
 
Open Educational Resources Primer PowerPoint
Open Educational Resources Primer PowerPointOpen Educational Resources Primer PowerPoint
Open Educational Resources Primer PowerPoint
 
The basics of sentences session 4pptx.pptx
The basics of sentences session 4pptx.pptxThe basics of sentences session 4pptx.pptx
The basics of sentences session 4pptx.pptx
 
Removal Strategy _ FEFO _ Working with Perishable Products in Odoo 17
Removal Strategy _ FEFO _ Working with Perishable Products in Odoo 17Removal Strategy _ FEFO _ Working with Perishable Products in Odoo 17
Removal Strategy _ FEFO _ Working with Perishable Products in Odoo 17
 
Mbaye_Astou.Education Civica_Human Rights.pptx
Mbaye_Astou.Education Civica_Human Rights.pptxMbaye_Astou.Education Civica_Human Rights.pptx
Mbaye_Astou.Education Civica_Human Rights.pptx
 
IATP How-to Foreign Travel May 2024.pdff
IATP How-to Foreign Travel May 2024.pdffIATP How-to Foreign Travel May 2024.pdff
IATP How-to Foreign Travel May 2024.pdff
 
The Last Leaf, a short story by O. Henry
The Last Leaf, a short story by O. HenryThe Last Leaf, a short story by O. Henry
The Last Leaf, a short story by O. Henry
 
slides CapTechTalks Webinar May 2024 Alexander Perry.pptx
slides CapTechTalks Webinar May 2024 Alexander Perry.pptxslides CapTechTalks Webinar May 2024 Alexander Perry.pptx
slides CapTechTalks Webinar May 2024 Alexander Perry.pptx
 

rheumatoud arthritis and polyarthritis ppt

  • 2. My patient was a 35 year old female from female ward of general medicine department. I.P NO. : 51979 D.O.A : 26.11.15
  • 3. SUBJECTIVE REASON FOR ADMISSION : c/o abdominal discomfort, joint pains. Vomiting past one month. PAST MEDICAL HISTORY : Patient is steroid dependent(can’t survive without these tablets) not k/c/o DM,HTN PAST MEDICATION HISTORY : on regular medication past 10 years. T. Dexamethasone 0.5mg T.Phenyl butazone
  • 4. KNOWN ALLERGIES : Nil SMOKER : No ALCOHOLIC : No TOBACCO IN ANY FORM : No MARITAL STATUS : Married
  • 5. OBJECTIVE LABORATORY INVESTIGATIONS: Blood Pressure, Cell Blood Count, Renal Function Test. GENERAL INVESTIGATION : Patient is conscious, weak, afebrile, poorly built. She is steroid dependent from past 10 years.
  • 6. LABORATORY REPORTS ELECTROLYTES Date 26-11-15 27-11-15 Blood Pressure 110/70 110/70 Electrolytes Normal value(mEq/L) Patient’s value(mEq/L) Sodium 130-150 134 Potassium 3.5-5.8 4.42 Chloride 98-100 106
  • 7. BLOOD COUNTS CELLS NORMAL VALUE PATIENT VALUE HEAMOGLOBIN (g/dl) M 12-16 F 11-14 10 TLC(cells/cumm) 5000-10000 9500 PLATELETS 1-3 lakh POLYMORPHS 40-60 65 LYMPHOCYTES 20-30 27 BASOPHILS 0-1 00 EOSINOPHILS 1-4 04 MONOCYTES 1-2 04
  • 8. RENAL FUNCTION TEST Normal Value Patient Value UREA(mg%) 15-45 61 URIC ACID(mg%) F 2-5 M 2-7 CREATININE(mg%) 0.6-1.4 2.6
  • 9. ASSESSMENT  Patient was diagnosed with Arthritis, Polyarthritis.  Patient was steroid dependent from past 10 years.  Patient had vomiting since one month.  Patient has abnormal urea and creatinine value. Urea - 61 mg% Creatinine - 2.6 mg%
  • 10. S.No TRADE NAME GENERIC NAME FREQU ENCY DAYS 01 Inj.Pantop IV (40mg) Pantoprazole sodium 1-0-1 26/11/15 to 29/11/15 02 Inj.Emest (4mg) Ondansetron 1-1-1 26/11/15 to 29/11/15 03 T.Dolo(650mg) Paracetamol 1-1-1 26/11/15 to 27/11/15 04 T.Dexamethasone (0.5mg) Dexamethasone 1-0-1/2 26/11/15 to 29/11/15 05 T.TRP Tremadol + Paracetamol 1-0-1 27/11/15 to 29/11/15 06 T.HCQ(200mg) Hydroxychloroqui ne sulphate 1-0-0 27/11/15 to 29/11/15 TREATMENT PLAN
  • 11. S.No. TRADE NAME GENERIC NAME FREQUE NCY DAYS 07 Pirox(40mg) Piroxicam 1-0-1 26/11/15 08 IVF 10NS Normal saline 50ml/hr 26/11/15 to 29/11/15
  • 12. DAY 1 • Patient had vomiting hence was very weak. • Normal saline IVF was given to compensate electrolyte loss. • Renal function test report showed some abnormalities in urea and serum creatinine level. • Inj.Pantop, Inj.Emeset, T. Dolo and Dexamethasone, Normal saline, Piroxicam was started. • Blood pressure was normal.
  • 13. DAY 2 • Patient now had less episodes of vomiting. • Piroxicam was stopped. • T.TRP, T.HCQ was started as she still had complance of sever joint pain. • All other medications were continued as per the treatment chart. • Blood pressure was recorded as normal.
  • 14. DAY 3 • No episodes of vomiting was noticed. • Emeset was continued to prevent vomiting due to side effects of other drugs(dexamethasone, tramadol, piroxicam) • Patient started showing positive signs to the treatment given. • Medications continued as per the treatment chart.
  • 15. DAY 4 • Patient feels better. • Medications continued as per the treatment chart.
  • 16. DRUG INTERRACTION • HCQ-ONDANSETRON : MAJOR Concurrent use of HCQ and QT prolonging agents may result in increased risk of QT prolongation. • ONDANSETRON-TRP : MODERATE Concurrent use of ondansetron and tramadol may result in reduced efficacy of tramadol. • Piroxicam, dexamethasone, tramadol, pantop, hydroxychloroquine sulfate are contraindicative in pregnant and lactating mothers.
  • 17. PHARMACIST INTERVENSION SUGGESSIONS TO PHYSICIAN: • Emeset should not be given with HCQ and Tramadol. • Drug duplication to be checked. • Phenylbutazone has to be discontinued as it has major side effect i.e kidney damage.(refer renal function test report) SUGGESSIONS TO PATIENT: • Inform physician in case of any side effects. • Donot discontinue Dexamethasone until directed by a physician as it has unpleasant withdrawal symptoms. • Increase intake of calcium rich food. • Take the medication properly as it will improve the quality of life.
  • 18. DISCHARGE CHART  No discharge medication is available